Simona Pagliuca

Vandoeuvre-les-nancy, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 103 publications

Clonal Hematopoiesis after Immune Suppression - Adaptive Remodeling without Evolution? Early Lessons from the RACE Trial.

Clonal Hematopoiesis after Immune Suppression - Adaptive Remodeling without Evolution? Early Lessons from the RACE Trial.

Journal: NEJM evidence
Published: April 28, 2026

HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Journal: Bone marrow transplantation
Published: April 14, 2026

Interindividual HLA evolutionary divergence in mismatched unrelated donor allo-HCT for malignant hematological disorders.

Interindividual HLA evolutionary divergence in mismatched unrelated donor allo-HCT for malignant hematological disorders.

Journal: Blood advances
Published: March 06, 2026

Fertility management and outcomes after CAR T-cell therapy: an international survey from the Cellular Therapy and Immunobiology working party of the European Society for Blood and Marrow Transplantation.

Fertility management and outcomes after CAR T-cell therapy: an international survey from the Cellular Therapy and Immunobiology working party of the European Society for Blood and Marrow Transplantation.

Journal: EClinicalMedicine
Published: February 04, 2026

Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study.

Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study.

Journal: The Lancet. Haematology
Published: January 30, 2026

Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Journal: The Lancet. Haematology
Published: January 12, 2026

PTCy or ATG for Matched Transplantation in Myelofibrosis.

PTCy or ATG for Matched Transplantation in Myelofibrosis.

Journal: American journal of hematology
Published: January 03, 2026

OUTCOMES OF PATIENTS OVER 70 YEARS TREATED WITH BREXU-CEL FOR R/R MANTLE CELL LYMPHOMA: A STUDY FROM THE CTIWP OF EBMT.

OUTCOMES OF PATIENTS OVER 70 YEARS TREATED WITH BREXU-CEL FOR R/R MANTLE CELL LYMPHOMA: A STUDY FROM THE CTIWP OF EBMT.

Journal: Blood advances
Published: December 12, 2025

Outcomes of patients over 70 years treated with brexu-cel for R/R mantle cell lymphoma: a study from the CTIWP of EBMT.

Outcomes of patients over 70 years treated with brexu-cel for R/R mantle cell lymphoma: a study from the CTIWP of EBMT.

Journal: Blood advances
Published: December 12, 2025

Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee.

Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee.

Journal: Bone marrow transplantation
Published: November 30, 2025

The neurotoxic legacy of CAR-T cells: where do we stand?

The neurotoxic legacy of CAR-T cells: where do we stand?

Journal: Therapeutic advances in neurological disorders
Published: September 12, 2025

Optimized GMP-grade Wharton's jelly's mesenchymal stromal cells manufacturing and administration protocol for Graft versus Host disease prevention.

Optimized GMP-grade Wharton's jelly's mesenchymal stromal cells manufacturing and administration protocol for Graft versus Host disease prevention.

Journal: Current research in translational medicine
Published: May 13, 2025
Showing 1-12 of 103

Last Updated: 09/26/2026